Genomics, proteomics and metabolomics: Their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 279-286

  Castro Santos, Patricia ^a   Laborde, Carlos M ^b   Díaz Peña, Roberto ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^b Clinical Biochemistry Laboratory   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Genomics; Metabolomics; Proteomics; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; GENETIC MARKER;

BLOOD ANALYSIS; DNA METHYLATION; EPIGENETICS; GEL ELECTROPHORESIS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; HISTONE MODIFICATION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; URINALYSIS; ANIMAL; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; METABOLOMICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS;

EID: 84929940942     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet 2001; 358: 903-11.
2. TOBóN GJ, YOUINOU P, SARAUX A: The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J Autoimmun 2010; 35: 10-4.
3. AREND WP, FIRESTEIN GS: Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012; 8: 573-86.
4. DEANE KD: Can rheumatoid arthritis be prevented?. Best Pract Res Clin Rheumatol 2013; 27: 467-85.
5. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
6. MacGREGOR AJ, SNIEDER H, RIGBY AS et al.: Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30-7.
7. vander CRUYSSEN B, HOFMANN IE, PEENE I et al.: Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann Rheum Dis 2007; 66: 364-9.
8. SHI J, KNEVEL R, SUWANNALAI P et al.: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108: 17372-7.
9. SHRIVASTAV AK, SINGH HV, RAIZADA A et al.: Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol (Madr) 2014; (in press).
10. BIZZARO N, TONUTTI E, TOZZOLI R, VILLALTA D: Analytical and diagnostic characteristics of 11 2nd-and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007; 53: 1527-33.
11. WANG JH, BYUN J, PENNATHUR S: Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010; 30: 500-11.
12. SZODORAY P, SZABO Z, KAPITANY A et al.: Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010; 9: 140-3.
13. van der HELM-van MIL AH, TOES RE, HUIZINGA TW: Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1694-6.
14. RAYCHAUDHURI S, SANDOR C, STAHL EA et al.: Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-6.
15. GREGERSEN PK, SILVER J, WINCHESTER RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
16. ÄRLESTIG L, MULLAZEGI M., KOKKONEN H, ROCKLöV J, RöNELID J, DAHLQVIST SR: Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012; 71: 825-9.
17. KOLFENBACH JR, DEANE KD, DERBER LA et al.: A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum 2009; 61: 1735-42.
18. DING B, PADYUKOV L, LUNDSTRöM E et al.: Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009; 60: 30-8.
19. LEE HS, LEE AT, CRISWELL LA et al.: Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med 2008; 14: 293-300.
20. VIGNAL C, BANSAL AT, BALDING DJ et al.: Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci. Arthritis Rheum 2009; 60: 53-62.
21. BEGOVICH AB, CARLTON VE, HONIGBERG LA et al.: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75: 330-7.
22. PLENGE RM, PADYUKOV L, REMMERS EF et al.: Replication of putative candidate-gene associations with rheumatoid arthritis in > 4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77: 1044-60.
23. STAHL EA, RAYCHAUDHURI S, REMMERS EF et al.: Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-14.
24. EYRE S, BOWES J, DIOGO D et al.: High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44: 1336-40.
25. OKADA Y, WU D, TRYNKA G et al.: Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506: 376-81.
26. HERUTH DP, GIBSON M, GRIGORYEV DN, ZHANG LQ, YE SQ: RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis. Cell Biosci 2012; 2: 43.
27. GALLIGAN CL, BAIG E, BYKERK V, KEYSTONE EC, FISH EN: Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes Immun 2007; 8: 480-91.
28. WATANABE N, ANDO K, YOSHIDA S et al.: Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 2002; 294: 1121-9.
29. DEL REY MJ, IZQUIERDO E, USATEGUI A et al.: The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 2010; 62: 3584-94.
30. KAMINSKY ZA, TANG T, WANG SC et al.: DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet 2009; 41: 240-5.
31. PLANT D, WILSON AG, BARTON A: Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev 2014; 10: 329-37.
32. NAKANO K, WHITAKER JW, BOYLE DL, WANG W, FIRESTEIN GS: DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 110-7.
33. NILE CJ, READ RC, AKIL M, DUFF GW, WILSON AG: Methylation status of a single CpG site in the IL-6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008; 58: 2686-93.
34. KAROUZAKIS E, GAY RE, MICHEL BA, GAY S, NEIDHART M: DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-22.
35. RICHARDSON B, SCHEINBART L, STRAHLER J, GROSS L, HANASH S, JOHNSON M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33: 1665-73.
36. LIU Y, ARYEE MJ, PADYUKOV L et al.: Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nature Biotech 2013; 31: 142-7.
37. KIM YI, LOGAN JW, MASON JB, ROUBENOFF R: DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. J Lab Clin Med 1996; 128: 165-72.
38. ELLIS JA, MUNRO JE, CHAVEZ RA et al.: Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease. Clin Epigenetics 2012; 4: 20.
39. GOWERS IR, WALTERS K, KISS-TOTH E, READ RC, DUFF GW, WILSON AG: Age-related loss of CpG methylation in the tumour necrosis factor promoter. Cytokine 2011; 56: 792-7.
40. KOUZARIDES T: Chromatin modifications and their function. Cell 2007; 128: 693-705.
41. STRIETHOLT S, MAURER B, PETERS MA, PAP T, GAY S: Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 2008; 10: 219-28.
42. GRABIEC AM, REEDQUIST KA: The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev 2013; 9: 311-18.
43. van LOOSDREGT J, BRUNEN D, FLESKENS V, PALS CE, LAM EW, COFFER PJ: Rapid temporal control of Foxp3 protein degradation by sirtuin-1. Plos One 2011; 6: e19047.
44. KAWABATA T, NISHIDA K, TAKASUGI K et al.: Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R133.
45. GRABIEC AM, KORCHYNSKY O, TAK PP, REEDQUIST KA: Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocytes and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-31.
46. ROMERO V, FERT-BOBER J, NIGROVIC PA et al.: Immune-mediated pore-forming pathways induce celular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med 2013; 5: 209ra150.
47. CHOWDHURY CS, GIAGLIS S, WALKER UA, BUSER A, HAHN S, HASLER P: Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther 2014; 16: R122.
48. DUROUX-RICHARD I, JORGENSEN C, APPARAILLY F: What do microRNAs mean for rheumatoid arthritis?. Arthritis Rheum 2012; 64: 11-20.
49. PAULEY KM, SATOH M, CHAN AL, BUBB MR, REEVES WH, CHAN EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 2008; 10: R101.
50. FULCI V, SCAPPUCCI G, SEBASTIANI GD et al.: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Human Immunol 2010; 71: 206-11.
51. MURATA K, YOSHITOMI H, TANIDA S et al.: Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010; 12: R86.
52. GORG A, BOGUTH G, HARDER A, SCHEIBE B, WILDGRUBER R, WEISS W: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21: 1037-53.
53. GYGI SP, ZHANG Y, ROCHON Y, AEBERSOLD R: Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci 2000; 97: 9390-5.
54. WU X, HASAN MA, CHEN JY: Pathway and network analysis in proteomics. J Theor Biol 2014; 362: 44-52.
55. ROSS PL, HUANG YN, MARCHESE JN et al.: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-69.
56. NOH R, PARK SG, JU JH et al.: Comparative proteomic analyses of synovial fluids and serums from rheumatoid arthritis patients. J Microbiol Biotechnol 2014; 24: 119-26.
57. ZHENG X, WU SL, HINCAPIE M, HANCOCK WS: Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 2009; 1216: 3538-45.
58. MATEOS J, LOURIDO L, FERNáNDEZ-PUENTE P et al.: Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics 2012; 75: 2869-78.
59. BALAKRISHNAN L, BHATTACHARJEE M, AHMAD S et al.: Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin Proteomics 2014; 11: 1.
60. LI XJ, XU M, ZHAO XQ et al.: Proteomic analysis of synovial fibroblast-like synoviocytes from rheumatoid arthritis. Clin Exp Rheumatol 2013; 31: 552-8.
61. PASIKANTI KK, HO PC, CHAN EC: Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871: 202-11.
62. OLIVER SG, WINSON MK, KELL DB, BAGANZ F: Systematic functional analysis of the yeast genome. Trends Biotechnol 1998; 16: 373-8.
63. GLASSBROOK N, BEECHER C, RYALS J: Metabolic profiling on the right path. Nat Biotechnol 2000; 18: 1142-3.
64. DUNN WB, BAILEY NJ, JOHNSON HE: Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606-25.
65. ISSAQ HJ, ABBOTT E, VEENSTRA TD: Utility of separation science in metabolomic studies. J Sep Sci 2008; 31: 1936-47.
66. NICHOLSON JK, WILSON ID: Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2003; 2: 668-76.
67. HARRIGAN GG, LAPLANTE RH, COSMA GN et al.: Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett 2004; 146: 197-205.
68. JOHNSON HE, BROADHURST D, KELL DB, THEODOROU MK, MERRY RJ, GRIFFITH GW: High-throughput metabolic fingerprinting of legume silage fermentations via Fourier transforms infrared spectroscopy and chemometrics. Appl Environm Microbiol 2004; 70: 1583-92.
69. LENZ EM, BRIGHT J, WILSON ID, MORGAN SR, NASH A: A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharmac Biomed Anal 2003; 33: 1103-15.
70. MADSEN RK, LUNDSTEDT T, GABRIELSSON J et al.: Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthr Res Ther 2011; 13: R19.
71. NAUGTON D, WHELAN M, SMITH EC, WILLIAMS R, BLAKE DR, GROOTVELD M: An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett 1993; 317: 135-8.
72. LABORDE CM, MOURIñO-ALVAREZ L, POSADA-AYALA M et al.: Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. Metabolomics 2014; 10: 414-24.
73. van WIETMARSCHEN HA, DAI W, van der KOOIJ AJ et al.: Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS One 2012; 7: e44331.
74. PRETE PE, GURAKAR-OSBORNE A, KASHYAP ML: Synovial fluid lipids and apolipoproteins: a contemporary perspective. Biorheology 1995; 32: 1-16.
75. WISE CM, WHITE RE, AGUDELO CA: Syn-ovial fluid lipid abnormalities in various disease states: review and classification. Semin Arthritis Rheum 1987; 16: 222-30.
76. GIERA M, IOAN-FACSINAY A, TOES R et al.: Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta 2012; 1821: 1415-24.
77. HüGLE T, KOVACS H, HEINEN IA et al.: Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol 2012; 30: 240-5.
78. DIOGO D, KURREEMAN F, STAHL EA et al.: Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWAS contribute to risk of rheumatoid arthritis. Am J Hum Genet 2013; 92: 15-27.